Comparative immunogenicity and safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine and 4vHPV vaccine administered according to two- or three-dose schedules in girls aged 9-14â¯years: Results to month 36 from a randomized trial.

Leung, Ting Fan; Liu, Anthony Pak-Yin; Lim, Fong Seng; Thollot, Franck; Oh, Helen May Lin; Lee, Bee Wah; Rombo, Lars; Tan, Ngiap Chuan; Rouzier, Roman; De Simoni, Stéphanie; Suryakiran, Pemmaraju; Hezareh, Marjan; Thomas, Florence; Folschweiller, Nicolas; Struyf, Frank

Comparative immunogenicity and safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine and 4vHPV vaccine administered according to two- or three-dose schedules in girls aged 9-14â¯years: Results to month 36 from a randomized trial.

Leung, Ting Fan; Liu, Anthony Pak-Yin; Lim, Fong Seng; Thollot, Franck; Oh, Helen May Lin; Lee, Bee Wah; Rombo, Lars; Tan, Ngiap Chuan; Rouzier, Roman; De Simoni, Stéphanie; Suryakiran, Pemmaraju; Hezareh, Marjan; Thomas, Florence; Folschweiller, Nicolas; Struyf, Frank.

Afiliação

Leung TF; Department of Paediatrics, The Chinese University of Hong Kong, Shatin, Hong Kong. Electronic address: tfleung@cuhk.edu.hk.
Liu AP; Department of Paediatrics and Adolescent Medicine, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong.
Lim FS; National Healthcare Group Polyclinics and National University of Singapore, Singapore.
Thollot F; Association Française de Pédiatrie Ambulatoire (AFPA), Essey Les Nancy, France.
Oh HML; Division of Infectious Disease, Changi General Hospital, Singapore.
Lee BW; Mount Elizabeth Medical Centre and National University of Singapore, Singapore.
Rombo L; Centre for Clinical Research, Sormland County Council, Uppsala University and Karolinska Institute, Stockholm, Sweden.
Tan NC; SingHealth Polyclinics and DUKE-NUS Graduate Medical School, Singapore, Singapore.
Rouzier R; Institut Curie, Paris, France.
De Simoni S; GSK, Rixensart, Belgium.
Suryakiran P; GSK, Bangalore, India.
Hezareh M; Chiltern International for GSK, Wavre, Belgium.
Thomas F; GSK, Wavre, Belgium.
Folschweiller N; GSK, Wavre, Belgium.
Struyf F; GSK, Wavre, Belgium.

Vaccine ; 36(1): 98-106, 2018 01 02.

Article em En | MEDLINE | ID: mdl-29174109

Assuntos

Anticorpos Antivirais/sangue; Esquemas de Imunização; Imunogenicidade da Vacina; Infecções por Papillomavirus/prevenção & controle; Vacinas contra Papillomavirus/efeitos adversos; Adjuvantes Imunológicos/administração & dosagem; Adjuvantes Imunológicos/efeitos adversos; Adolescente; Hidróxido de Alumínio/administração & dosagem; Formação de Anticorpos/imunologia; Linfócitos B/imunologia; Linfócitos T CD4-Positivos/imunologia; Criança; Estudos de Coortes; Feminino; Papillomavirus Humano 16/genética; Papillomavirus Humano 16/imunologia; Papillomavirus Humano 18/genética; Papillomavirus Humano 18/imunologia; Humanos; Imunidade Celular; Imunização/métodos; Imunização/estatística & dados numéricos; Testes de Neutralização; Papillomaviridae/imunologia; Infecções por Papillomavirus/virologia; Vacinas contra Papillomavirus/administração & dosagem

Palavras-chave

Administration schedule; Female adolescents; Human papillomavirus vaccines; Immunogenicity; Safety

Texto completo

Adicionar na Minha BVS

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Esquemas de Imunização / Infecções por Papillomavirus / Vacinas contra Papillomavirus / Imunogenicidade da Vacina / Anticorpos Antivirais Tipo de estudo: Clinical_trials / Etiology_studies / Guideline / Incidence_studies / Observational_studies / Risk_factors_studies Limite: Adolescent / Child / Female / Humans Idioma: En Revista: Vaccine Ano de publicação: 2018 Tipo de documento: Article País de publicação: Holanda

Texto completo

Adicionar na Minha BVS

Imprimir

XML

PubMed Links

Buscar no Google